John Gnann to Herpes Zoster
This is a "connection" page, showing publications John Gnann has written about Herpes Zoster.
Connection Strength
2.629
-
Herpes zoster in the age of focused immunosuppressive therapy. JAMA. 2009 Feb 18; 301(7):774-5.
Score: 0.307
-
Vaccination to prevent herpes zoster in older adults. J Pain. 2008 Jan; 9(1 Suppl 1):S31-6.
Score: 0.284
-
Clinical practice. Herpes zoster. N Engl J Med. 2002 Aug 01; 347(5):340-6.
Score: 0.195
-
Herpes zoster: focus on treatment in older adults. Antiviral Res. 1999 Dec 31; 44(3):145-54.
Score: 0.163
-
Herpes zoster: risk categories for persistent pain. J Infect Dis. 1999 Jan; 179(1):9-15.
Score: 0.152
-
Therapeutic approaches to the management of herpes zoster. Adv Exp Med Biol. 1999; 458:159-65.
Score: 0.152
-
Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group. Antimicrob Agents Chemother. 1998 May; 42(5):1139-45.
Score: 0.145
-
Herpes zoster in patients with human immunodeficiency virus infection--an ever-expanding spectrum of disease. Clin Infect Dis. 1995 Oct; 21(4):989-90.
Score: 0.121
-
New antivirals with activity against varicella-zoster virus. Ann Neurol. 1994; 35 Suppl:S69-72.
Score: 0.107
-
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis. 2013 Nov 01; 208(9):1386-90.
Score: 0.104
-
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013 Aug 15; 208(4):559-63.
Score: 0.103
-
Varicella-zoster virus: Prevention through vaccination. Clin Obstet Gynecol. 2012 Jun; 55(2):560-70.
Score: 0.096
-
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012 Apr; 54(7):922-8.
Score: 0.094
-
Natural history and treatment of varicella-zoster in high-risk populations. J Hosp Infect. 1991 Jun; 18 Suppl A:317-29.
Score: 0.090
-
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009 Apr; 142(3):209-217.
Score: 0.077
-
The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008 Mar 01; 197 Suppl 2:S207-15.
Score: 0.072
-
Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008 Jan; 9(1 Suppl 1):S37-44.
Score: 0.071
-
Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 01; 44 Suppl 1:S1-26.
Score: 0.066
-
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 02; 352(22):2271-84.
Score: 0.059
-
A mixed model for factors predictive of pain in AIDS patients with herpes zoster. J Pain Symptom Manage. 1999 Jun; 17(6):410-7.
Score: 0.039
-
Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996 Sep 01; 125(5):376-83.
Score: 0.032
-
Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host. Antiviral Res. 1996 Jan; 29(1):67-8.
Score: 0.031
-
Acyclovir: a decade later. N Engl J Med. 1992 Sep 10; 327(11):782-9.
Score: 0.025
-
Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J Infect Dis. 1992 Mar; 165(3):450-5.
Score: 0.024
-
Acyclovir: the past ten years. Adv Exp Med Biol. 1990; 278:243-53.
Score: 0.020